BRPI0412979A - composição probiótica lìquida, método para a preparação da composição probiótica lìquida e método para tratar um paciente - Google Patents

composição probiótica lìquida, método para a preparação da composição probiótica lìquida e método para tratar um paciente

Info

Publication number
BRPI0412979A
BRPI0412979A BRPI0412979-2A BRPI0412979A BRPI0412979A BR PI0412979 A BRPI0412979 A BR PI0412979A BR PI0412979 A BRPI0412979 A BR PI0412979A BR PI0412979 A BRPI0412979 A BR PI0412979A
Authority
BR
Brazil
Prior art keywords
probiotic composition
liquid probiotic
bacteria
composition
patient
Prior art date
Application number
BRPI0412979-2A
Other languages
English (en)
Inventor
Nellie Kelner-Padalka
Original Assignee
Bio Balance Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Balance Corp filed Critical Bio Balance Corp
Publication of BRPI0412979A publication Critical patent/BRPI0412979A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO PROBIóTICA LìQUIDA, MéTODO PARA A PREPARAçãO DA COMPOSIçãO PROBIóTICA LìQUIDA E MéTODO PARA TRATAR UM PACIENTE". Um método para preparar uma composição probiótica líquida, compreendendo bactérias tendo pelo menos uma atividade biológica basal, na qual tais bactérias foram selecionadas de acordo com pelo menos uma pressão de seleção, onde a composição preferivelmente inclui um autolisado (substâncias completas para manter bactérias) e na qual a composição está substancialmente livre de substâncias apropriadas para a reprodução bacteriana mas nao igualmente apropriada para mamíferos, e particularmente não apropriada para seres humanos. Peptonas e sais tampões, particularmente fosfatos, podem não ser nocivos em pequenas doses, mas não especificamente apropriados para seres humanos e livres de substâncias geradas por bactérias.
BRPI0412979-2A 2003-08-18 2004-08-16 composição probiótica lìquida, método para a preparação da composição probiótica lìquida e método para tratar um paciente BRPI0412979A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49571403P 2003-08-18 2003-08-18
PCT/IL2004/000749 WO2005017095A2 (en) 2003-08-18 2004-08-16 A stable liquid probiotic composition, preparation and applications thereof

Publications (1)

Publication Number Publication Date
BRPI0412979A true BRPI0412979A (pt) 2006-10-03

Family

ID=34193337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412979-2A BRPI0412979A (pt) 2003-08-18 2004-08-16 composição probiótica lìquida, método para a preparação da composição probiótica lìquida e método para tratar um paciente

Country Status (12)

Country Link
US (1) US20050042207A1 (pt)
EP (1) EP1656025A4 (pt)
JP (1) JP2007518693A (pt)
KR (1) KR20060073937A (pt)
CN (1) CN1867258A (pt)
AU (1) AU2004265511A1 (pt)
BR (1) BRPI0412979A (pt)
CA (1) CA2535892A1 (pt)
MX (1) MXPA06001821A (pt)
RU (1) RU2006108554A (pt)
WO (1) WO2005017095A2 (pt)
ZA (1) ZA200601391B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
KR20060109452A (ko) * 2003-10-02 2006-10-20 더 바이오 밸런스 코포레이션 건조 바이오치료 조성물, 용도, 그 투여 장치 및 투여 방법
US20070009490A1 (en) * 2003-10-02 2007-01-11 Conte Anthony E Dried biotherapeutic composition, uses, and device and methods for administration thereof
MY143693A (en) 2004-03-24 2011-06-30 Nestec Sa Shelf stable product wih living micro-organisms
FR2901138A1 (fr) * 2006-05-19 2007-11-23 Lesaffre & Cie Compositions de micro-organismes probiotiques, granules les contenant, leur procede de preparation et leurs utilisations
WO2008109669A2 (en) * 2007-03-05 2008-09-12 Om Pharma Bacterial extract for respiratory disorders and proces for its preparation
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN103687604A (zh) * 2011-03-01 2014-03-26 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
RU2504388C1 (ru) * 2012-11-22 2014-01-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Комбинированный антибактериальный препарат для лечения острых кишечных инфекций
RU2513204C1 (ru) * 2012-11-22 2014-04-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения комбинированного антибактериального препарата для лечения острых кишечных инфекций
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) * 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
AU2014212003C1 (en) 2013-02-04 2020-07-16 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017125845A1 (en) 2016-01-19 2017-07-27 Synergia Life Sciences Pvt. Ltd A liquid probiotic composition stable at ambient temperature
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
CA3062868A1 (en) * 2016-08-01 2018-02-08 Scaled Microbiomics, Llc Systems and methods for altering microbiome to reduce disease risk and manifestations of disease
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
JP7104435B2 (ja) * 2018-02-28 2022-07-21 腸内フローラ移植臨床研究株式会社 生体微生物含有組成物及びその製造方法
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
KR20210065969A (ko) 2018-09-27 2021-06-04 핀치 테라퓨틱스 홀딩스 엘엘씨 간질 및 관련 장애를 치료하기 위한 조성물 및 방법
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
US11576937B2 (en) * 2020-02-06 2023-02-14 Nch Corporation Method of reducing gut inflammation reduction in humans by consuming a heated probiotic composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518696A (en) * 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
GB8700354D0 (en) * 1987-01-08 1987-02-11 Distillers Co Culture of micro-organisms
US4910024A (en) * 1988-07-05 1990-03-20 Micro Chemical, Inc. Method and apparatus for administering live bacteria as feed additives to livestock and poultry
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5139792A (en) * 1990-07-19 1992-08-18 Bio-Techniques Laboratories, Inc. Method and system for dispensing live bacteria into animal feed and drinking water
GB9107305D0 (en) * 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
US5340577A (en) * 1992-07-29 1994-08-23 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
US5733568A (en) * 1993-12-03 1998-03-31 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
DE19751907B4 (de) * 1997-11-22 2004-07-08 Pharma-Zentrale Gmbh Verwendung von Escherichia coli Stamm DSM 6601 zur Behandlung von Diarrhoeen auf dem Veterinärsektor
US6706287B2 (en) * 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
WO2002043649A2 (en) * 2000-11-30 2002-06-06 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
IL130303A0 (en) * 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use
JP4671384B2 (ja) * 2001-05-15 2011-04-13 雪印乳業株式会社 新規乳酸菌株
RU2253672C2 (ru) * 2002-07-12 2005-06-10 Хачатрян Ашот Папикович Бактериальный пробиотический препарат
ITBO20020564A1 (it) * 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
KR20060073937A (ko) 2006-06-29
EP1656025A2 (en) 2006-05-17
AU2004265511A1 (en) 2005-02-24
CN1867258A (zh) 2006-11-22
CA2535892A1 (en) 2005-02-24
RU2006108554A (ru) 2007-09-27
WO2005017095A2 (en) 2005-02-24
MXPA06001821A (es) 2006-05-31
US20050042207A1 (en) 2005-02-24
EP1656025A4 (en) 2007-12-05
ZA200601391B (en) 2007-04-25
JP2007518693A (ja) 2007-07-12
WO2005017095A3 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
BRPI0412979A (pt) composição probiótica lìquida, método para a preparação da composição probiótica lìquida e método para tratar um paciente
Gristina et al. Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis.
Schreml et al. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mammaplasty
Polak et al. Incorporating antibiotics into platelet‐rich fibrin: a novel antibiotics slow‐release biological device
Bongers et al. Reinfection and re-revision rates of 113 two-stage revisions in infected TKA
Baysan et al. Use of microwave energy to disinfect a long-term soft lining material contaminated with Candida albicans or Staphylococcus aureus
Otten et al. Bacterial colonization on different suture materials—a potential risk for intraoral dentoalveolar surgery
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
Gahukamble et al. Propionibacterium acnes and Staphylococcus lugdunensis cause pyogenic osteomyelitis in an intramedullary nail model in rabbits
Hikmawati et al. Synthesis and Characterization of Nanohydroxyapatite‐Gelatin Composite with Streptomycin as Antituberculosis Injectable Bone Substitute
Höing et al. Bioactive glass granules inhibit mature bacterial biofilms on the surfaces of cochlear implants
Chang Cultural, Cytoloǵical and Ecoloǵical Observations on the Amoeba Stage of Naeǵleria gruberi
Scevola et al. Allogenic platelet gel in the treatment of pressure sores: a pilot study
Winter et al. Intermittent versus continuous stretching effects on osteoblast‐like cells in vitro
Saito et al. Acceleration of bone formation during fracture healing by injectable collagen powder and human basic fibroblast growth factor containing a collagen‐binding domain from Clostridium histolyticum collagenase
Kuehling et al. A human bone infection organ model for biomaterial research
Kasukonis et al. Development of an infusion bioreactor for the accelerated preparation of decellularized skeletal muscle scaffolds
Farnsworth et al. The effect of implanting gentamicin‐impregnated polymethylmethacrylate beads in the tarsocrural joint of the horse
Meloni et al. Recombinant human FGF18 preserves depth dependent mechanical inhomogeneity in articular cartilage
DE69012329D1 (de) Bakterielle mittel zur verwendung bei geflügel.
Karoussis et al. Osteostimulative calcium phosphosilicate biomaterials partially restore the cytocompatibility of decontaminated titanium surfaces in a peri‐implantitis model
ATE292382T1 (de) Zur inaktivierung von infektiösen proteinen behandelte zusammensetzungen
Sawada et al. Antiseptic solutions modulate the paracrine‐like activity of bone chips: differential impact of chlorhexidine and sodium hypochlorite
RU2640391C1 (ru) Способ выбора тактики лечения больных с перипротезной инфекцией

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A01N 63/00; A61K 35/78; C12N 1/00; C12N 1/20.

Ipc: C12N 1/04 (2006.01), A23L 2/52 (2006.01), A23L 33/

Ipc: C12N 1/04 (2006.01), A23L 2/52 (2006.01), A23L 33/